Univariate and multivariate analysis of potential risk factors for developing grade III/IV acute GVHD among patients who received NIMA-complementary stem cell transplantation for advanced hematologic malignancies
Variable . | Risk category . | Unadjusted odds ratio (95% CI) . | P . | Adjusted odds ratio (95% CI) . | P . |
|---|---|---|---|---|---|
| No. of mismatched HLA Ags: GVH direction | 3 Ag | 2.71 (0.53-13.92) | .23 | 2.97 (0.48-18.5) | .24 |
| No. of mismatched HLA Ags: HVG direction | 1 Ag increase | 0.69 (0.28-1.72) | .43 | - | - |
| Type of GVH target: IPA vs NIMA* | IPA | 6.75 (1.11-41.0) | .04 | 9.88 (1.22-79.7) | .03 |
| Recipient age, y | 20 or more | 0.88 (0.17-4.57) | .88 | 2.33 (0.30-17.9) | .42 |
| Donor-recipient sex combination† | Female to male | 1.04 (0.20-5.26) | .96 | - | - |
| Disease status | Chemorefractory | 0.63 (0.13-3.08) | .56 | - | - |
| Type of conditioning: reduced intensity vs standard intensity | Standard intensity | 1.59 (0.26-9.54) | .61 | - | - |
| Type of conditioning: TBI-containing vs non-TBI | TBI-containing | 1.04 (0.20-5.34) | .96 | - | - |
| GVHD prophylaxis | With corticosteroids | 1.40 (0.21-9.12) | .73 | - | - |
Variable . | Risk category . | Unadjusted odds ratio (95% CI) . | P . | Adjusted odds ratio (95% CI) . | P . |
|---|---|---|---|---|---|
| No. of mismatched HLA Ags: GVH direction | 3 Ag | 2.71 (0.53-13.92) | .23 | 2.97 (0.48-18.5) | .24 |
| No. of mismatched HLA Ags: HVG direction | 1 Ag increase | 0.69 (0.28-1.72) | .43 | - | - |
| Type of GVH target: IPA vs NIMA* | IPA | 6.75 (1.11-41.0) | .04 | 9.88 (1.22-79.7) | .03 |
| Recipient age, y | 20 or more | 0.88 (0.17-4.57) | .88 | 2.33 (0.30-17.9) | .42 |
| Donor-recipient sex combination† | Female to male | 1.04 (0.20-5.26) | .96 | - | - |
| Disease status | Chemorefractory | 0.63 (0.13-3.08) | .56 | - | - |
| Type of conditioning: reduced intensity vs standard intensity | Standard intensity | 1.59 (0.26-9.54) | .61 | - | - |
| Type of conditioning: TBI-containing vs non-TBI | TBI-containing | 1.04 (0.20-5.34) | .96 | - | - |
| GVHD prophylaxis | With corticosteroids | 1.40 (0.21-9.12) | .73 | - | - |
CI indicates confidence interval; Ags, antigens; IPA, inherited paternal HLA antigen; NIMA, noninherited maternal HLA antigen; TBI, total-body irradiation.
Comparing maternal donor (GVH target: IPA) with offspring or NIMA-mismatched sibling donor (GVH target: NIMA)
Comparing transplants from female donors (mothers, female offspring, and female siblings) into male recipients with those performed in the other donor-recipient sex pairs
Indicates not done